Elaine Ku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elaine Ku has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
Charles E. McCulloch
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
33 shared publicationsKirsten L. Johansen
Division of Nephrology, Department of Medicine, Hennepin Healthcare Institute, Minneapolis, MN
21 shared publications- Charles E. McCulloch
University of California, San Francisco
18 shared publications Barbara A. Grimes
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
13 shared publicationsFeng Lin
Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco California USA
11 shared publicationsChi-Yuan Hsu
Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA
10 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11)
Transplant Care and Immunosuppression Practices at Pediatric Kidney Transplant Centers and Their Association With Re‐transplantation After Graft Failure
Background: There is a paucity of data on how to manage children with failed kidney transplants in order to optimize their access to future transplants. Our objective was to understand how system‐level differences in transplant care and immunosuppression management after graft failure are associated with access to a second kidney transplant in children. Methods: To achieve our objective, we surveyed US pediatric kidney transplant centers about their practices. We then examined the relation between each center's approach in delivering follow‐up care, transitioning care, and immunosuppression management after graft failure with access of children to re‐transplantation between 2005 and 2019 according to the US Renal Data System using Fine‐Gray models. Results: 43/84 surveyed programs who served 1388 pediatric patients with graft failure responded. Although programs had variable practices in terms of frequency of follow‐up visits and age of transition from pediatric to adult care, these practices were not associated with access to re‐transplantation. Regarding immunosuppression management, pediatric kidney transplant recipients at centers whose respondents did not oversee the weaning of immunosuppression after graft failure had a 37% reduced likelihood of re‐transplantation (95% CI: 17%–53%). Centers that continued immunosuppression in children receiving dialysis after graft failure until there was no residual graft function had a 39% reduced likelihood of re‐transplantation (95% CI: 17%–55%) compared to centers that withdrew immunosuppression after a pre‐defined period. Conclusions: Management of pediatric transplant recipients with graft failure is variable at US pediatric kidney transplant centers, and variability in immunosuppression management practices was associated with the likelihood of re‐transplantation.
- 8 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11)
Open AccessTransplant Care and Immunosuppression Practices at Pediatric Kidney Transplant Centers and Their Association With Re‐transplantation After Graft Failure
Background: There is a paucity of data on how to manage children with failed kidney transplants in order to optimize their access to future transplants. Our objective was to understand how system‐level differences in transplant care and immunosuppression management after graft failure are associated with access to a second kidney transplant in children. Methods: To achieve our objective, we surveyed US pediatric kidney transplant centers about their practices. We then examined the relation between each center's approach in delivering follow‐up care, transitioning care, and immunosuppression management after graft failure with access of children to re‐transplantation between 2005 and 2019 according to the US Renal Data System using Fine‐Gray models. Results: 43/84 surveyed programs who served 1388 pediatric patients with graft failure responded. Although programs had variable practices in terms of frequency of follow‐up visits and age of transition from pediatric to adult care, these practices were not associated with access to re‐transplantation. Regarding immunosuppression management, pediatric kidney transplant recipients at centers whose respondents did not oversee the weaning of immunosuppression after graft failure had a 37% reduced likelihood of re‐transplantation (95% CI: 17%–53%). Centers that continued immunosuppression in children receiving dialysis after graft failure until there was no residual graft function had a 39% reduced likelihood of re‐transplantation (95% CI: 17%–55%) compared to centers that withdrew immunosuppression after a pre‐defined period. Conclusions: Management of pediatric transplant recipients with graft failure is variable at US pediatric kidney transplant centers, and variability in immunosuppression management practices was associated with the likelihood of re‐transplantation.
- 2 July 2026
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 33 (2) , 153-159
Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?
- 2 July 2026
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 33 (2) , 153-159
Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?
- Open Access
- 7 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70373
Association Between Age at Kidney Transplantation and Risk of Early Graft Loss
Background: Adolescence has been identified as a high‐risk period for graft failure. However, existing knowledge on this topic is largely limited to long‐term graft outcomes. The aim of this study was to examine the association between age at kidney transplantation and early graft loss, defined as graft failure within 3 years post‐transplantation in the contemporary era. Methods: This study was a retrospective analysis of 55 973 first‐time kidney transplant recipients identified in the U.S. Renal Data System from January 1, 2005, to December 31, 2021. Adjusted Cox proportional hazards regression models were used to evaluate the association between age at transplantation and early graft failure including an interaction term for race/ethnicity. Results: Adolescents (12 to < 18 years) and young adults (18 to < 26 years) were at the highest risk of early death‐censored graft loss compared to young adults (26 to < 40 years), with hazard ratios of 1.95 (95% CI 1.74–2.17) and 2.01 (95% CI 1.86–2.17), respectively. Additionally, we found that the effect of age on early graft loss varied significantly by race, with disparities observed among Asian and Black youth. Conclusion: These findings highlight a persistently elevated risk in adolescents and young adults in the contemporary era.
- 7 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70373
Open AccessAssociation Between Age at Kidney Transplantation and Risk of Early Graft Loss
Background: Adolescence has been identified as a high‐risk period for graft failure. However, existing knowledge on this topic is largely limited to long‐term graft outcomes. The aim of this study was to examine the association between age at kidney transplantation and early graft loss, defined as graft failure within 3 years post‐transplantation in the contemporary era. Methods: This study was a retrospective analysis of 55 973 first‐time kidney transplant recipients identified in the U.S. Renal Data System from January 1, 2005, to December 31, 2021. Adjusted Cox proportional hazards regression models were used to evaluate the association between age at transplantation and early graft failure including an interaction term for race/ethnicity. Results: Adolescents (12 to < 18 years) and young adults (18 to < 26 years) were at the highest risk of early death‐censored graft loss compared to young adults (26 to < 40 years), with hazard ratios of 1.95 (95% CI 1.74–2.17) and 2.01 (95% CI 1.86–2.17), respectively. Additionally, we found that the effect of age on early graft loss varied significantly by race, with disparities observed among Asian and Black youth. Conclusion: These findings highlight a persistently elevated risk in adolescents and young adults in the contemporary era.
- Open Access
- 6 April 2026
- Published by Springer Nature in Pediatric Nephrology
- p. 1-10
Association between estimated time with low glomerular filtration rate and access to transplant among youth with advanced chronic kidney disease
Background: Slower chronic kidney disease (CKD) progression allows more time for transplant preparation. Whether differences in CKD progression by race/ethnicity associate with preemptive or living donor transplantation in youth has not been well studied. Methods: We examined the association between time spent with low eGFR (between 10–30 mL/min/1.73 m 2 ) and odds of preemptive or living donor transplantation among youth with CKD. eGFR was estimated using the bedside Schwartz (if < 18 years) and CKD-EPI 2021 equations (if ≥ 18 years) and the CKiD U25 equation in sensitivity analysis. Time spent with low eGFR was compared by race/ethnicity. Results: Among 333 youth with CKD (median age 11 years [IQR 7,14]), median time spent with low eGFR was 28.8 months. 77% were preemptively waitlisted, and 45% received preemptive transplantation (56% of White and 24% of Black youth). Black (vs. White) youth had shorter time with low eGFR (–6.5 months; 95% CI –11.5, –1.4). Time with low eGFR did not differ across other groups. Findings were similar using the U25 equation. Every additional year spent with low eGFR was associated with higher odds of preemptive (OR 1.45; 95% CI 1.24–1.70) and living donor transplantation (OR 1.42; 95% CI 1.21–1.67), but not preemptive waitlisting (OR 0.96; 95% CI 0.83–1.11) in unadjusted analyses. Conclusions: Longer time spent with low eGFR is associated with greater odds of preemptive and living donor transplantation. Earlier transplant referral for all children, especially Black youth, may help improve access to preemptive and living donor transplantation. Graphical
- 6 April 2026
- Published by Springer Nature in Pediatric Nephrology
- p. 1-10
Open AccessAssociation between estimated time with low glomerular filtration rate and access to transplant among youth with advanced chronic kidney disease
Background: Slower chronic kidney disease (CKD) progression allows more time for transplant preparation. Whether differences in CKD progression by race/ethnicity associate with preemptive or living donor transplantation in youth has not been well studied. Methods: We examined the association between time spent with low eGFR (between 10–30 mL/min/1.73 m 2 ) and odds of preemptive or living donor transplantation among youth with CKD. eGFR was estimated using the bedside Schwartz (if < 18 years) and CKD-EPI 2021 equations (if ≥ 18 years) and the CKiD U25 equation in sensitivity analysis. Time spent with low eGFR was compared by race/ethnicity. Results: Among 333 youth with CKD (median age 11 years [IQR 7,14]), median time spent with low eGFR was 28.8 months. 77% were preemptively waitlisted, and 45% received preemptive transplantation (56% of White and 24% of Black youth). Black (vs. White) youth had shorter time with low eGFR (–6.5 months; 95% CI –11.5, –1.4). Time with low eGFR did not differ across other groups. Findings were similar using the U25 equation. Every additional year spent with low eGFR was associated with higher odds of preemptive (OR 1.45; 95% CI 1.24–1.70) and living donor transplantation (OR 1.42; 95% CI 1.21–1.67), but not preemptive waitlisting (OR 0.96; 95% CI 0.83–1.11) in unadjusted analyses. Conclusions: Longer time spent with low eGFR is associated with greater odds of preemptive and living donor transplantation. Earlier transplant referral for all children, especially Black youth, may help improve access to preemptive and living donor transplantation. Graphical
- 16 March 2026
- Published by Wolters Kluwer Health in Transplantation
- Vol. 110 (6) , e1343-e1344
AI-assisted Qualitative Research on Kidney Failure Treatment Decisions
Visual abstract is available online at doi.org/10.1097/TP.0000000000005685. Export
- 16 March 2026
- Published by Wolters Kluwer Health in Transplantation
- Vol. 110 (6) , e1343-e1344
AI-assisted Qualitative Research on Kidney Failure Treatment Decisions
Visual abstract is available online at doi.org/10.1097/TP.0000000000005685. Export
- 16 March 2026
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
Stopping renin–angiotensin–aldosterone system inhibitors in kidney disease
Purpose: The KDIGO guidelines recommend the use of renin–angiotensin system inhibitors (RASi) in chronic kidney disease (CKD) given their kidney and cardiovascular benefits. Despite this recommendation, real-word data suggest low rates of the use of these medications, and RASi are frequently discontinued. The objective of this review is to summarize the outcomes associated with the discontinuation of RASi in individuals with CKD, hyperkalemia, and acute kidney injury (AKI). Recent findings: Trial-grade data suggest that there is no benefit to the discontinuation of RASi in patients with low eGFR on kidney or mortality outcomes. Observational and trial-grade data suggests similar outcomes for the continuation of RASi during the perioperative period as compared to discontinuation of RASi. Observational data also suggest that reinitiation of RASi after AKI and hyperkalemia is associated with improved survival and reduces the risk of progression of kidney disease. Summary: This review highlights outcomes following the discontinuation of RASi, which is generally associated with worse outcomes across the spectrum of CKD, hyperkalemia, and AKI.
- 16 March 2026
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
Stopping renin–angiotensin–aldosterone system inhibitors in kidney disease
Purpose: The KDIGO guidelines recommend the use of renin–angiotensin system inhibitors (RASi) in chronic kidney disease (CKD) given their kidney and cardiovascular benefits. Despite this recommendation, real-word data suggest low rates of the use of these medications, and RASi are frequently discontinued. The objective of this review is to summarize the outcomes associated with the discontinuation of RASi in individuals with CKD, hyperkalemia, and acute kidney injury (AKI). Recent findings: Trial-grade data suggest that there is no benefit to the discontinuation of RASi in patients with low eGFR on kidney or mortality outcomes. Observational and trial-grade data suggests similar outcomes for the continuation of RASi during the perioperative period as compared to discontinuation of RASi. Observational data also suggest that reinitiation of RASi after AKI and hyperkalemia is associated with improved survival and reduces the risk of progression of kidney disease. Summary: This review highlights outcomes following the discontinuation of RASi, which is generally associated with worse outcomes across the spectrum of CKD, hyperkalemia, and AKI.
- Open Access
- 12 March 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (5) , 101325
Association Between Time Spent With Low Posttransplant Glomerular Filtration Rate and Access to Relisting and Retransplantation
- 12 March 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (5) , 101325
Open AccessAssociation Between Time Spent With Low Posttransplant Glomerular Filtration Rate and Access to Relisting and Retransplantation
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (3) , e1916
Understanding the Relationship Between Severe Donor Diabetes Insipidus, Kidney Donor Profile Index, and Recipient Kidney Function
Background.: Severe diabetes insipidus (DI) causes dynamic changes in creatinine before organ donation. It is unknown whether terminal or peak creatinine is the optimal measure of graft quality among donors with severe DI. Methods.: Adult donors after brain death were identified from the United Network for Organ Sharing database, years 2015–2022. Kidney Donor Profile Index (KDPI) was computed using both terminal creatinine (KDPI-Terminal) and peak creatinine (KDPI-Peak). Model fit for the prediction of graft failure and reduced glomerular filtration rate (GFR) was compared. Logistic regression was used to determine the association between KDPI group reclassification and graft function. Results.: Of 28 718 kidney transplants, 29% of donors met criteria for severe DI. No differences in estimated GFR (eGFR) or all-cause graft failure were observed on the basis of the presence of DI. Among donors with severe DI, KDPI-Peak improved prediction of reduced eGFR at 1 y (eGFR 2 , eGFR 2 ). Additionally, patients who received organs from donors with severe DI whose KDPI group would be reclassified on the basis of the use of peak rather than terminal creatinine had 2-fold increased odds of reduced eGFR at 1 y (eGFR 2 ; odds ratio, 1.92; 95% confidence interval, 1.37-2.69). Conclusions.: This national analysis confirms that while the presence of severe DI alone is not associated with graft outcomes, the use of peak creatinine significantly improves risk stratification of donor graft quality. Precise risk stratification is critical for efforts to improve appropriate kidney allocation and increase confidence in organ function after transplant.
- 17 February 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (3) , e1916
Open AccessUnderstanding the Relationship Between Severe Donor Diabetes Insipidus, Kidney Donor Profile Index, and Recipient Kidney Function
Background.: Severe diabetes insipidus (DI) causes dynamic changes in creatinine before organ donation. It is unknown whether terminal or peak creatinine is the optimal measure of graft quality among donors with severe DI. Methods.: Adult donors after brain death were identified from the United Network for Organ Sharing database, years 2015–2022. Kidney Donor Profile Index (KDPI) was computed using both terminal creatinine (KDPI-Terminal) and peak creatinine (KDPI-Peak). Model fit for the prediction of graft failure and reduced glomerular filtration rate (GFR) was compared. Logistic regression was used to determine the association between KDPI group reclassification and graft function. Results.: Of 28 718 kidney transplants, 29% of donors met criteria for severe DI. No differences in estimated GFR (eGFR) or all-cause graft failure were observed on the basis of the presence of DI. Among donors with severe DI, KDPI-Peak improved prediction of reduced eGFR at 1 y (eGFR 2 , eGFR 2 ). Additionally, patients who received organs from donors with severe DI whose KDPI group would be reclassified on the basis of the use of peak rather than terminal creatinine had 2-fold increased odds of reduced eGFR at 1 y (eGFR 2 ; odds ratio, 1.92; 95% confidence interval, 1.37-2.69). Conclusions.: This national analysis confirms that while the presence of severe DI alone is not associated with graft outcomes, the use of peak creatinine significantly improves risk stratification of donor graft quality. Precise risk stratification is critical for efforts to improve appropriate kidney allocation and increase confidence in organ function after transplant.
- 16 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (1) , e70443
Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients
The gold standard approach to the diagnosis of rejection in kidney transplant recipients currently relies on tissue obtained during biopsies. However, repeat performance of biopsies is cumbersome, and use of dd‐cfDNA in conjunction with eGFR may help inform whether ongoing rejection may be persistent after a diagnosis of rejection is made by biopsy and anti‐rejection treatment administered. In this single‐center prospective study, 52 patients with rejection were followed longitudinally over time with quarterly dd‐cfDNA measurements, of whom 78% had repeat biopsies to confirm the presence or absence of persistent rejection. With every 1 percentage point higher baseline (“first”) dd‐cfDNA levels drawn at time of enrollment, the odds of persistent rejection were 1.35 (95% CI 1.18‐1.55) higher. With every 1 percentage point increase in the slope of dd‐cfDNA levels over time, the odds of persistent rejection were 1.62 times higher (95% CI 1.10‐2.38). Models including only baseline and the slope of dd‐cfDNA provided moderate risk discrimination for rejection (c = 0.73), which improved to c = 0.75 with the addition of eGFR at baseline and change in eGFR over time. Monitoring of dd‐cfDNA may offer reasonable discrimination of the likelihood of persistent rejection following anti‐rejection therapy. Further validation of these findings is needed.
- 16 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (1) , e70443
Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients
The gold standard approach to the diagnosis of rejection in kidney transplant recipients currently relies on tissue obtained during biopsies. However, repeat performance of biopsies is cumbersome, and use of dd‐cfDNA in conjunction with eGFR may help inform whether ongoing rejection may be persistent after a diagnosis of rejection is made by biopsy and anti‐rejection treatment administered. In this single‐center prospective study, 52 patients with rejection were followed longitudinally over time with quarterly dd‐cfDNA measurements, of whom 78% had repeat biopsies to confirm the presence or absence of persistent rejection. With every 1 percentage point higher baseline (“first”) dd‐cfDNA levels drawn at time of enrollment, the odds of persistent rejection were 1.35 (95% CI 1.18‐1.55) higher. With every 1 percentage point increase in the slope of dd‐cfDNA levels over time, the odds of persistent rejection were 1.62 times higher (95% CI 1.10‐2.38). Models including only baseline and the slope of dd‐cfDNA provided moderate risk discrimination for rejection (c = 0.73), which improved to c = 0.75 with the addition of eGFR at baseline and change in eGFR over time. Monitoring of dd‐cfDNA may offer reasonable discrimination of the likelihood of persistent rejection following anti‐rejection therapy. Further validation of these findings is needed.
- 31 October 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (7) , 1-9
Exploring Racial and Ethnic Disparities in Outcomes Following Pediatric Cardiac Surgery: A NEPHRON Study Analysis
Objective Racial and ethnic disparities in neonatal postoperative outcomes are reported, but differences in cardiac surgery-associated acute kidney injury (CS-AKI) remain unexamined. We assessed racial/ethnic disparities in CS-AKI prevalence and outcomes in neonates undergoing congenital heart surgery. Design, Setting, and Patients Retrospective cohort of neonates across 22 centers (2015–2018) from the Pediatric Cardiac Critical Care Consortium and the Neonatal and Pediatric Heart and Renal Outcomes Network. Measurements Race/ethnicity (primary predictor) were categorized into eight groups; CS-AKI was defined using neonatal modified Kidney Disease: Improving Global Outcomes criteria as mild (stage 1), severe (≥ stage 2) and persistent (any stage beyond post-operative day [POD] 3). Outcomes included not achieving net negative fluid balance [FB], respiratory support duration, length of stay [LOS], and mortality. Multivariable regression models examining the association between race/ethnicity and outcomes were also constructed. Results Among 2,165 neonates (2% Asian, 18% Hispanic, 1% multi-racial, 0.3% Native American, 14% Non-Hispanic Black (NHB), 59% Non-Hispanic White (NHW), 5% other, and 0.2% Pacific Islander), CS-AKI prevalence (31% mild, 23% severe) did not differ across racial/ethnic groups. NHB neonates had lower birthweight and higher surgical complexity, while NHW neonates had higher private insurance rates. NHB neonates were less likely to not achieve a net negative FB until ≥ POD3 than NHW neonates, but no differences were found in respiratory support duration, hospital LOS, or mortality after multivariate adjustment. Non-white neonates with severe AKI had higher mortality but had similar clinical outcomes. Conclusions CS-AKI rates did not vary by race/ethnicity. Differences in fluid balance achievement were noted but no significant disparities were found in mortality, mechanical ventilation duration, or hospital LOS.
- 31 October 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (7) , 1-9
Exploring Racial and Ethnic Disparities in Outcomes Following Pediatric Cardiac Surgery: A NEPHRON Study Analysis
Objective Racial and ethnic disparities in neonatal postoperative outcomes are reported, but differences in cardiac surgery-associated acute kidney injury (CS-AKI) remain unexamined. We assessed racial/ethnic disparities in CS-AKI prevalence and outcomes in neonates undergoing congenital heart surgery. Design, Setting, and Patients Retrospective cohort of neonates across 22 centers (2015–2018) from the Pediatric Cardiac Critical Care Consortium and the Neonatal and Pediatric Heart and Renal Outcomes Network. Measurements Race/ethnicity (primary predictor) were categorized into eight groups; CS-AKI was defined using neonatal modified Kidney Disease: Improving Global Outcomes criteria as mild (stage 1), severe (≥ stage 2) and persistent (any stage beyond post-operative day [POD] 3). Outcomes included not achieving net negative fluid balance [FB], respiratory support duration, length of stay [LOS], and mortality. Multivariable regression models examining the association between race/ethnicity and outcomes were also constructed. Results Among 2,165 neonates (2% Asian, 18% Hispanic, 1% multi-racial, 0.3% Native American, 14% Non-Hispanic Black (NHB), 59% Non-Hispanic White (NHW), 5% other, and 0.2% Pacific Islander), CS-AKI prevalence (31% mild, 23% severe) did not differ across racial/ethnic groups. NHB neonates had lower birthweight and higher surgical complexity, while NHW neonates had higher private insurance rates. NHB neonates were less likely to not achieve a net negative FB until ≥ POD3 than NHW neonates, but no differences were found in respiratory support duration, hospital LOS, or mortality after multivariate adjustment. Non-white neonates with severe AKI had higher mortality but had similar clinical outcomes. Conclusions CS-AKI rates did not vary by race/ethnicity. Differences in fluid balance achievement were noted but no significant disparities were found in mortality, mechanical ventilation duration, or hospital LOS.